Development of Lipid Nanoparticle-Based mRNA Delivery Systems for Targeted Pharmacogenomic Therapy
Keywords:
mRNA delivery, lipid nanoparticles, pharmacogenomics, targeted therapy, precision medicineAbstract
Messenger RNA (mRNA)-based therapeutics have witnessed accelerated advancement in recent years, particularly driven by the clinical success of mRNA vaccines against COVID-19. A key component enabling their efficacy is the use of lipid nanoparticles (LNPs) as delivery vehicles. In the context of pharmacogenomics, personalized mRNA therapies offer the potential to tailor drug responses based on individual genetic profiles. This paper explores recent developments in LNP-based mRNA delivery systems specifically optimized for targeted pharmacogenomic applications. It examines literature on LNP design, tissue targeting strategies, and safety enhancements. Two diagrams and a comparative table of LNP formulations are provided to visualize progress in the field. By contextualizing these findings within the broader trend toward precision medicine, we highlight future pathways for clinical translation in genetically guided therapies.
References
[1] Hou, X., et al. “Lipid Nanoparticles for mRNA Delivery.” Nature Reviews Materials, vol. 6, no. 12, 2021, pp. 1078–94.
[2] Sahin, Ugur, et al. “mRNA-Based Therapeutics—Developing a New Class of Drugs.” Nature Reviews Drug Discovery, vol. 13, no. 10, 2014, pp. 759–80.
[3] Li, B., Zhang, X., and Dong, Y. “Lipid Nanoparticles for mRNA Delivery.” Nature Reviews Materials, vol. 6, no. 12, 2021, pp. 1078–94.
[4] Pardi, Norbert, et al. “mRNA Vaccines—A New Era in Vaccinology.” Nature Reviews Drug Discovery, vol. 17, no. 4, 2018, pp. 261–79.
[5] Sago, Christopher D., et al. “High-Throughput In Vivo Screen of Functional mRNA Delivery Identifies Nanoparticles for Endothelial Cell Gene Editing.” Proceedings of the National Academy of Sciences, vol. 115, no. 42, 2018, pp. E9944–52.
[6] Patel, Sonal, et al. “Influence of Ionizable Lipids on the Pharmacokinetics and Biodistribution of Lipid Nanoparticles Containing siRNA.” International Journal of Pharmaceutics, vol. 530, no. 1–2, 2017, pp. 129–38.
[7] Cheng, Qiaozhi, et al. “Selective Organ Targeting (SORT) Nanoparticles for Tissue-Specific mRNA Delivery and CRISPR–Cas Gene Editing.” Nature Nanotechnology, vol. 15, no. 4, 2020, pp. 313–20.
[8] Eygeris, Yevgeny, et al. “Mechanism of mRNA Delivery by Lipid Nanoparticles.” Cell Reports, vol. 38, no. 3, 2022, Article 110271.
[9] Liu, Lijuan, et al. “Lipid Nanoparticle-Mediated mRNA Delivery: Challenges and Future Perspectives.” Nano Today, vol. 38, 2021, Article 101394.
[10] Buschmann, Matthias D., et al. “Nanomaterial Delivery Systems for mRNA Vaccines.” Vaccines, vol. 9, no. 1, 2021, p. 65.
[11] Kaczmarek, Joanna C., Kevin J. Kauffman, and Daniel G. Anderson. “Advances in the Delivery of RNA Therapeutics: From Concept to Clinical Reality.” Genome Medicine, vol. 9, no. 1, 2017, p. 60.
[12] Kowalski, Phillip S., et al. “Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.” Molecular Therapy, vol. 27, no. 4, 2019, pp. 710–28.
